Anupam Rama
JPMorgan Chase & Co, Research Division
All right. Welcome, everyone, to the 44th Annual J.P. Morgan Healthcare Conference. My name is Anupam Rama. I’m one of the senior biotech analysts here at J.P. Morgan. I’m joined by my squad, Priyanka Grover, Joyce Zhou and Rati Pinhe. Our next presenting company is Kodiak. And presenting on behalf of the company, we have CEO, Victor Perlroth. Victor?
Victor Perlroth
Co-Founder, Chairman, CEO & President
Thank you, Anupam. Well, each year at the J.P. Morgan, the metronome of the different years, it’s great to be here. Thank you. But I also remember the R&D Day that Kodiak had in July of last year. I think at that time, I said I couldn’t be more excited and enthusiastic about what we had in front of us. And now looking 6 months later, we’ve made tremendous progress on the plans that we articulated at that time. I think what I also like to say is many good things that could have happened did happen and many bad things that could have happened didn’t. I think as I look and as we look at Kodiak to 2026 and into 2027, it’s a tremendously exciting time for us. I continue to be very pleased with all of the progress and everything that I see at the company.
We’re going to, as usual, run through quite a lot of content. There is a lot under the hood at Kodiak, and we’ll try to do that in a time-efficient manner. First, remember our forward-looking statements. Please read carefully all of the SEC documentations, including the
Read the full article here
